Form 8-K - Current report:
SEC Accession No. 0001144204-18-009432
Filing Date
2018-02-16
Accepted
2018-02-16 08:39:59
Documents
5
Period of Report
2018-02-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tv486366_8k.htm 8-K 30325
2 EXHIBIT 1.1 tv486366_ex1-1.htm EX-1.1 155535
3 EXHIBIT 4.1 tv486366_ex4-1.htm EX-4.1 99180
4 EXHIBIT 5.1 tv486366_ex5-1.htm EX-5.1 8051
5 EXHIBIT 10.1 tv486366_ex10-1.htm EX-10.1 237625
  Complete submission text file 0001144204-18-009432.txt   531902
Mailing Address 2575 WEST BELLFORT SUITE 333 HOUSTON TX 77054
Business Address 2575 WEST BELLFORT SUITE 333 HOUSTON TX 77054 713-300-5160
Moleculin Biotech, Inc. (Filer) CIK: 0001659617 (see all company filings)

EIN.: 474671999 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37758 | Film No.: 18619752
SIC: 2834 Pharmaceutical Preparations